Research-use proteomics that maps and analyzes proteins to help identify biomarkers.
Consented intake · your records travel with you · nothing moves without your sign-off
Seer offers proteomics, the mapping and analysis of proteins using mass spectrometry or target capture, with blood or FFPE tissue as input. This kind of analysis can model signature pathways to identify biomarkers. Seer's platform is research use only and may not currently focus on cancer, so patients should treat it as a research resource, not a clinical test.
Prefer the source? Seer (RUO, not doing cancer?)'s own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Seer (RUO, not doing cancer?) handles billing.
We don't have confirmed insurance details for Seer (RUO, not doing cancer?) yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Seer's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Finds clinical trials you actually qualify for — matched to your tumor's biomarkers and treatment history, not a generic keyword search.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.